FDA scolds Sun Pharmaceutical for serious quality control problems at a key plant in India

Sun Pharmaceutical, one of the world’s largest generic drugmakers, was scolded by the U.S. Food and Drug Administration for a host of serious manufacturing violations at a key plant in India, the latest instance in which the company was tagged by the regulator for quality-control problems.

In a Dec. 15 warning letter posted on Tuesday on the FDA website, Sun was cited for several notable failures, such as not following appropriate procedures to prevent contamination; establishing an adequate system for monitoring environmental conditions; using suitable equipment; thoroughly investigating discrepancies in batches of products; or cleaning and sterilizing equipment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

No Byline Policy

Editorial Guidelines

Corrections Policy

Source